Sedana Medical submits application for market approval in UK
Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the company has submitted an application for market approval for the drug candidate Sedaconda (isoflurane) for inhaled sedation in intensive care in the UK.“Through this application, we cover another important European market ahead of our upcoming launch. If all goes well, we expect to be able to launch in the second half of 2021 in the first 15 European countries for which we have already submitted an application. In the UK, we expect to be able to launch in the first half of 2022," said Christer Ahlberg, CEO of Sedana